Ains-To confirm the recent data obtained in mice, showing that the Fas ligand (FasL) is involved in the phenomenon of "immune privilege"(the apparent defect ofthe immune system in specific anatomical sites) and to extend this finding to humans. Methods-The expression of FasL was analysed in a panel of histologically normal human tissues by reverse transcriptase polymerase chain reaction and Western blotting. The tissues sampled were brain, breast, bone marrow, oesophagus, kidney, liver, lung, lymph node, ovary, pancreas, pituitary gland, prostate, spleen, stomach (antrum and fundus), striated muscle, testis, thyroid, and uterus. These were obtained from patients with various neoplastic and nonneoplastic disorders; placental tissue was obtained after normal obstetric delivery, and spontaneous or voluntary abortion. Results-Strong FasL expression was detected in testis and placenta. FasL expression was also detectable, although it was seen to a lesser extent, in oesophagus, prostate, lung, and uterus, which also coexpressed variable amounts of Fas mRNA or protein or both. The other organs tested for FasL expression were all negative. Conclusions-FasL in humans is expressed predominantly in immune "sanctuaries" such as testis and placenta, suggesting that, similar to mice, this expression may contribute to the immune privileged status of these organs, by preventing dangerous inflammatory responses. The coexpression ofFasL and Fas in particular epithelia suggests that the physiological cell turnover of some tissues may be regulated by the Fas-FasL apoptotic pathway.
Fas/CD95 and its ligand (FasL) are members of two superfamilies of complementary receptors and ligands, respectively, that play important roles in immune regulation.' Fas, also called APO-1,2I is a 45 kDa type I membrane protein belonging to the tumour necrosis factor receptor (TNFR) superfamily that includes the p55 and p75 TNFRs, the low affinity nerve growth factor receptor, CD27, CD30, CD40, OX40, and 4-1BB. 4 Among these receptors, Fas and the p55 TNFR share a 70 amino acid intracellular "death domain" that transduces signals for cell death.5 Fas mediates apoptosis when cross-linked with agonistic anti-Fas antibodies. 6 FasL is a 40 kDa type II membrane protein expressed as a membrane bound form that is proteolytically processed into a soluble cytokine retaining biological activity. 8'- There is increasing evidence from lpr and gld mice models that CD95/CD95 ligand mediated apoptosis is a crucial regulatory process which limits immune response and provides a safeguard against emergence of autoreactive lymphocytes.'2 '3 lpr mutant mice harbour either an early transposable element or a mutation in the Fas gene, which either reduces severely the expression of a full size Fas transcript, or abolishes its ability to transduce an apoptotic signal.'2 gld mice harbour a point mutation in the extracellular domain of FasL'4 15; this mutation abolishes the binding between FasL and its receptor. Mice carrying a homozygous mutation for either lpr or gld develop similar phenotypes, characterised by massive lymphadenopathy, splenomegaly, B cell activation, and hypergammaglobulinaemia. 12 13 Lymphadenopathy in lpr and gld mice results from the expansion of a nonneoplastic subset of chronically activated cells that are TCR+, CD3+, CD4, and CD8-(doubly negative T cells).'2 13 The major immune defect in lpr and gld mice appears to be the defective TCR induced death of mature T cells, which results in a failure in peripheral, rather than thymic, T cell deletion.'2 13 The human counterpart of lpr mice is the recently described auto-immune lymphoproliferative syndrome, caused by dominant interfering Fas mutations.16 Affected children have a defect in apoptosis of phenotypically normal mature T cells, and present with acccumulation of doubly negative T cells in spleen and lymph nodes. '6 17 Because of its capacity to induce apoptosis of T cells, FasL has been thought to be involved in the phenomenon of "immune privilege". ' were activated with 2.5 jg/ml of PHA and 30 U/ml of recombinant human interleukin-2 (IL-2) (Proleukin, Chiron, France), then grown for four days in medium containing 20 ng/ml IL-2. Cells were restimulated with 1 ng/ml of phorbol myristic acetate (PMA, Sigma) and 500 ng/ml of concanavalin A (ConA, Sigma) for 24 hours as described previously" prior to poly(A)+ RNA preparation.22
RT-PCR ANALYSIS OF FASL AND FAS EXPRESSION
Total RNAs were prepared from frozen tissues by lysis in guanidium isothiocyanate.22 Reverse transcription was performed as described previously,23 using 1 pg of poly(A)+ RNA from control cells, and 1 jg of total RNA from tissues. One quarter of the cDNA preparation was used for FasL amplification using a 20-mer sense oligonucleotide (5'-CTACAGGAC TGAG AAGAAGT-Y') upstream of the initiation codon, and a 22-mer antisense oligonucleotide (5'-CAACATTCTCGGTGCCTGTA AC-3') downstream of the termination codon.'0 Oligonucleotide primers for Fas (sense primer, 5'-GTAAAG TATAGTATTT GAGTGCAG-3' (nucleotide positions 1718-1744), and antisense primer, 5'-CATT TTCGGGGGTGG-3' (positions 2175-2191)) were in the non-coding region; they both amplify mature mRNAs.2 3Integrity of RNA samples had been proved by means of electrophoresis of an aliquot on denaturing agarose/formaldehyde gel, and was further checked by performing control amplification for human 1B actin (sense primer, 5'-TACCACTGGCATCGT GATGGACT-3', and antisense primer 5'-TCCTTCTGCA TCCTGTCGGCAAT-3'). The cDNA was mixed with 50 jl of a PCR mixture containing the reaction buffer and 2.5 U of Taq polymerase (Perkin Elmer Cetus, New Jersey, USA). The PCR cycle profile was as follows: denaturation (94°C for one minute (two minutes for the first cycle)), annealing (55°C for two minutes), and extension (72°C for three minutes (10 minutes for the last cycle)); 30 cycles of amplification were used. PCR products were visualised in ethidium bromide stained 1.5% agarose gels.
SOUTHERN BLOT ANALYSIS
PCR products separated by means of gel electrophoresis were transferred to Hybond N+ membranes (Amersham, Buckinghamshire, UK) as recommended by the manufacturer. Membranes were prehybridised for two hours at 45°C in 5 x SSC containing 0.1 % laurylsarcosin, 0.02% SDS and 0.5% blocking reagent (Boehringer Mannheim, France). They were hybridised overnight at 45°C in the same buffer containing a digoxigenin labelled internal oligonucleotide: an 18-mer (CAAAT AG-GCCACCCCAGT, spanning the 3' end of exon 2 and the 5' end of exon 3) for FasL, and a 24-mer (5'-ACATGTCATGAACCCATG TTTGCA-3' (nucleotide positions 2118-2142)) for Fas, respectively. Oligonucleotide probes were labelled with a 3' tailing kit (Boehringer Mannheim) according to the supplier's recommendations. After hybridisation, filters were washed twice for 10 minutes at room temperature in 2 x SSC containing 0.1 % SDS, and twice for 10 minutes at 55°C in 0.1 x SSC containing 0.1% SDS, then visualised using a chemiluminescence detection kit (Boehringer Mannheim). WESTERN may be the basis of the particular immui tus of the eye and testis known as "immune privilege". To determine whether FasL expression could represent the basis of immune privilege in humans, we studied FasL mRNA expression and localisation by using RT-PCR to analyse various organs, including those known to act as immune sanctuaries. We found that FasL expression was confined to a few specific sites, in good correlation with earlier findings in mice.
Expression of FasL mRNA has been reported in rodent but not in human testis.'8 Testis has long been known to be a remarkably immune priviledged site; rat testis, when placed in the abdominal cavity, allows the successful transplantation of both allografts and xenografts. 20 The expression of FasL in human testis reported here suggests that similar mechanism(s) could underlie immune privilege in mice and humans. Testicular FasL might induce apoptosis of T cells activated in response to tumour antigens, thereby favouring the growth ofneoplastic cells. Such a hypothesis may help to explain particular clinical observations, like the agressive behaviour of primary testicular lymphomas which frequently relapse in the controlateral testis.34 It may be that one of the purposes of immune privilege in the testis could be to arrest the spread of dangerous inflammatory responses, potentially able to destroy germinal cells and thus threaten the fate of the species.
The demonstration of FasL expression in the placenta is of special interest, as the mechanisms preventing rejection of the embryo by the maternal immune system are subject to speculation. Preliminary immunohistochemical analysis of FasL expression seemed to AW localise the staining in the fetal trophoblast covering the placental villi (Xerri, unpublished observation 
